Watch IPO: Filjart twenty & super specialty Files diles for IPO. Check details

IPO Clock: Gujarat Kidney & Super Support, Regional Health Companies, Submit Fresh Scripts can be in the Market

The public offer proposed, consists of a total sale 2.2 shares as well as the goods are available.

The company plans to spend funds that raise funds through IPO for purchasing funds, equipment and work requirements.

According to DRHP filed by the company, the process from fresh problems in the horizon ₹77 crore will be used to offer to receive a parekhs hospital at Ahmedabad, ₹12.4 crore for paying for part purchase guarantee for Ashwini Medical Center that has purchased, ₹30.2 crore for funding support funding to reset new hospital in Vadodara, ₹7.3 crore for buying robot equipment for the hospital in Vadoodra, and ₹1.5 crore for repayment and / or prepaid payments of the safest loan is a safe loan obtained by the company. In addition, it has said that the remaining funds will be used to support the investigation in the purpose of the company and generalized companies.

In the IPO, 75% of the issue is reserved for qualified institutions, and no more than 15% of non-institutions and retail.

About Gujarar Kidney & Super Spenty

Gujarat Kidney & Super Specialty is one of the regional health care companies located in Gujarat. It operates a chain of chain of medium mediums of health medical services, focusing on secondary care and three.

On March 20, 2025, in a combination background, it has the ability to store 400 beds, beds, beds. In addition, there are three pharmacies operating within its hospital.

The company is led by the management of management and manager with directors, who have experienced more than a decade in the urine industry.

Blossa Gujarat and Restricted Limited Restrictions ₹34.01 crore in budget 2023 to ₹41.04 crore in budget 2024. Profit after tax grows from ₹2.80 crore in budget 2023 to ₹4.34 crore in budget 2024.

Nirbhay Purifical Pumpalle Limper is a leader manager by India’s stock and BSE’s market market.

Refuse: Opinion and recommendations of the above mentioned persons are those of personal analysts or chickens, and not of mint. We recommend the investor audited a certified expert before deciding any investment.